Samsara Bio Capital, LLC Viracta Therapeutics, Inc. Transaction History
Samsara Bio Capital, LLC
- $173 Million
- Q3 2024
A detailed history of Samsara Bio Capital, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 689,709 shares of VIRX stock, worth $158,633. This represents 0.09% of its overall portfolio holdings.
Number of Shares
689,709
Previous 689,709
-0.0%
Holding current value
$158,633
Previous $372,000
57.53%
% of portfolio
0.09%
Previous 0.19%
Shares
4 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$349,6550.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$219,5310.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$115,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$76,4030.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$66,3710.03% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $8.64M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...